Despite the recent stock market rally and declining volatility, IPOs are rather rare in many industrialised countries –not least for seasonal reasons. The main reason for this, however, is the aggressive monetary policy of the central banks, with more than ten interest rate hikes in both Europe and the US.
Roche opens €90m gene therapy development centre
Latest NewsBasel-headquartered Roche AG has inaugurated a brand new €90m gene therapy development centre in Penzberg near Munich.
AstraZeneca to take over Fusion Therapeutics Inc
Latest NewsBritish pharma giant AstraZeneca has announced to acquire radio-conjugate specialist Fusion Therapeutics Inc for US$2bn upfront.
Senisca Ltd raises £3.7m seed money
Latest NewsExeter-based university spin-out Senisca Ltd has added £3.7m seed money to a £1.1m not dilutive funding to advance its pipeline of drugs targetting RNA splicing dysregulation.
Are there bright times for biotech IPOs ahead?
OpinionDespite the recent stock market rally and declining volatility, IPOs are rather rare in many industrialised countries –not least for seasonal reasons. The main reason for this, however, is the aggressive monetary policy of the central banks, with more than ten interest rate hikes in both Europe and the US.
Meeting rising demand
Sponsored PublicationsRadiopharmaceutical Therapy (RPT) is offering several advantages over existing therapeutic strategies. The highly sought-after therapeutics require a sophisticated supply chain, as radioisotopes have short half-lives and must be delivered to patients with extreme speed and efficiency. ITM rises to this challenge as one of the largest global providers and developers of medical radioisotopes for this novel therapy.
A novel BPM system
BackgroundThe biotech and pharma branch is growing steadily. Many companies have full order books for the next few years and expect growth. This is the basis for new investments in assets and infrastructure. These growing structures often expose vulnerabilities and challenges for the business. Therefore, companies need to increase the stability and efficiency of their processes.
AstraZeneca to acquire Amolyt Pharma for up to US$1.05bn
Latest NewsFrench endocrine diseases specialist Amolyt Pharma SA has entered into a take-over agreement by AstraZeneca.
Relation Therapeutics Ltd bags US$35m in seed financing.
Latest NewsLondon-based virtual drug discovery specialist Relation Therapeutics Ltd has closed another US$35m seed financing round, bringing its total seed fundraise to US$60m.
Researcher find potential target for atherosclerosis
Latest NewsTREM2, a receptor on the surface of macrophages, reduces necrotic core formation in early atherosclerosis, a German-Austrian reseach team reports.
Cultivated meat debate clouded by misinformation
OpinionAs cultivated meat moves closer to commercialisation, we are seeing a worrying trend of misinformation entering the public debate. This food can play a vital role in ensuring Europe’s food system is fit for the future – helping satisfy the growing demand for meat while boosting food security – but political opposition has mounted, with the Italian government taking the controversial step of banning cultivated meat.